Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 130.80% | -665.45% | 102.86% | 2.24% | -636.02% |
| Total Depreciation and Amortization | -0.53% | 1.08% | 4.49% | 4.09% | 4.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -539.75% | 77.73% | -121.76% | 1.67% | 4,315.55% |
| Change in Net Operating Assets | 82.72% | -2,651.81% | 105.28% | 33.12% | -777.61% |
| Cash from Operations | 10.32% | -65.60% | -34.90% | 34.72% | -13.36% |
| Capital Expenditure | -96.36% | 86.22% | -3,225.00% | 14.29% | 85.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 279.13% | 84.79% | -- | -- | -100.00% |
| Cash from Investing | 270.25% | 84.83% | -127,683.33% | 14.29% | -100.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 35.71% | 6.67% | 6.25% | -14.29% | 0.00% |
| Issuance of Common Stock | -20.30% | -72.47% | 879.59% | -- | -- |
| Repurchase of Common Stock | 100.00% | -3,900.00% | -- | 100.00% | -333.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -1.75% | -1.79% |
| Cash from Financing | -19.69% | -72.71% | 1,011.18% | 697.39% | -106.09% |
| Foreign Exchange rate Adjustments | 5,280.00% | -102.78% | 4,600.00% | -101.37% | 501.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 129.72% | -1,497.12% | 119.30% | 67.70% | -380.03% |